Yüklüyor......
Therapy Preferences in Melanoma Treatment - Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls
BACKGROUND: New melanoma therapies, like e.g. ipilimumab, improve survival. However, only a small subset of patients benefits while 60% encounter side effects. Furthermore, these marginal benefits come at a very high price of €110’000 per treatment. This study examines attitudes towards melanoma the...
Kaydedildi:
| Yayımlandı: | PLoS One |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Public Library of Science
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4219712/ https://ncbi.nlm.nih.gov/pubmed/25369124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0111237 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|